Manar Anton. Msc Pmp, Qbd

Manar Anton has a comprehensive work experience in the pharmaceutical industry. Currently, they serve as the R&D Director for Dar Al Dawa Development & Investment Co since January 2023. Prior to this role, they were the Head of Research and Development at Pharmaline / Malia Group from April 2021 to December 2022. Manar Anton has also held various positions at Tabuk Pharmaceuticals Manufacturing Company, starting as a Senior Research & Development Supervisor for sterile products and nonsterile liquid and semisolid from October 2010 to December 2014. Manar also served as the Research and Development Manager from January 2018 to March 2021 and as an Assistant Manager from January 2015 to December 2017. Earlier in their career, Manar Anton worked as an Injectable Development Supervisor at Tabuk R&D, Tabuk Pharmaceutical Mfg. Co from October 2010 to July 2011. Additionally, they were a Senior Formulation Pharmacist at Tabuk Pharmaceutical Mfg. Co from August 2006 to September 2009, and started their career as a Pharmacist at Pharmacare Pharmacy in 2006. Overall, Manar Anton brings a wealth of experience in R&D, product development, and regulatory compliance to their current role.

Manar Anton has a strong educational background in the pharmaceutical field. Manar obtained their Bachelor of Science degree in Pharmacy from Jordan University of Science & Technology, where they studied from 2001 to 2006. Building on their undergraduate education, they pursued a Master of Science degree in Pharmaceutical Technology at King's College London, completing their studies from 2009 to 2010.

In addition to their formal education, Manar Anton has also obtained significant certifications. Manar became a Project Management Professional (PMP) in July 2022, receiving this certification from the Project Management Institute. Furthermore, they have also obtained a certification in "Quality by Design (QbD)" from QbD-Expert™ in May 2022. This certification focuses on practical implementation of tools and tactics of QbD and L6σ in pharmaceutical products development.